趋化因子及其受体在肝癌中的功能及预后价值

摘要/Abstract

摘要： 目的通过分析TCGA数据库中的肝癌样本联合GTEx数据库中的正常样本,探讨趋化因子受体(CCRs)在肝癌中的重要性。方法收集66个CCRs,筛选差异表达的CCRs,并进行GO功能注释和KEGG通路富集分析,以探索其潜在的生物学功能。使用单因素及多因素Cox回归分析并联合Lasso回归分析,构建了基于四个CCRs(CCR9、CCR7、CCR3和ACKR2)特征的预测评分模型,构建列线图来评估HCC患者的预后并进行免疫分析。结果我们发现风险评分是HCC的独立预后因素。免疫分析提示风险评分与免疫细胞浸润有相关性,表明模型中CCRs可能在HCC免疫微环境中发挥关键作用。结论我们构建了一个预测模型,该模型可用于指导HCC患者的个性化治疗和预后的预测。

关键词: 趋化因子, 趋化因子受体, 肝癌预后, 免疫浸润

Abstract: Objective To explored the importance of chemokine and chemokine receptors (CCRs) in liver cancer by analyzing liver cancer samples in TCGA database and normal samples in GTEx database. Methods We first collected 66 CCRs, then screened the differentially expressed CCRs between the liver cancer and normal liver databases. GO functional annotation and KEGG pathway analysis was performed to explore their potential biological functions. By using univariate Cox regression and multivariate Cox regression analyses combined with Lasso regression analysis, we constructed a prediction model based on four-CCRs (CCR9、CCR7、CCR3 and ACKR2) signature. Next, a nomogram was constructed to assess the prognosis of HCC patients. Results We found that the risk score of this model was an independent prognostic factor of HCC. The correlation between the risk score and immune-cell infiltration as indicated by the four-CCRs signature might play a pivotal role in liver cancer immune microenvironment. Conclusion We constructed a prediction model which might guide personalized treatment and prognosis for liver cancer patients.

Key words: Chemokine, chemokine receptors, prognosis of liver cancer, immune cell infiltration

冯洁, 蔡勋全, 潘勤聪. 趋化因子及其受体在肝癌中的功能及预后价值[J]. 肝脏, 2024, 29(3): 293-299.

FENG Jie, CAI Xun-quan, PAN Qin-cong. The function and prognostic value of chemokines and their receptors in hepatocellular carcinoma[J]. Chinese Hepatolgy, 2024, 29(3): 293-299.

参考文献

[1] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2018,68(2):723-750.
[2] Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer[J]. Biol Chem,2017,398(8):817-837.
[3] The Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma[J]. Cell,2017,169(7):1327-1341.
[4] Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail[J]? Am J Gastroenterol,2013,108(3):425-432.
[5] Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer≤2 cm: results from two Western centers[J]. Hepatology,2013,57(4):1426-1435.
[6] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet,2018,391(10127):1301-1314.
[7] Sanchez J, Lane JR, Canals M, et al. Influence of chemokine N-terminal modification on biased agonism at the chemokine receptor CCR1[J]. Int J Mol Sci,2019,20(10):1-15.
[8] Massara M, Bonavita O, Mantovani A, et al. Atypical chemokine receptors in cancer: friends or foes[J]? J Leukoc Biol,2016,99(6): 927-933.
[9] Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more[J]. Nat Rev Immunol,2006,6(12):907-918.
[10] Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J]. Gastroenterology,2013,144(3):512-527.
[11] Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences[J]. Immunity,2019,51(1):27-41.
[12] Balkwill FR. The chemokine system and cancer[J]. J Pathol,2012,226(2):148-157.
[13] Lin L, Chen YS, Yao YD, et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer[J]. Oncotarget,2015,6(33):34758-34773.
[14] Liang K, Liu YR, Eer D, et al. High CXC chemokine ligand 16 (CXCL16) expression promotes proliferation and metastasis of lung cancer via regulating the NF-κB pathway[J]. Med Sci Monit,2018,24:405-411.
[15] Yang XL, Liu KY, Lin FJ, et al. CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis[J]. Oncol Rep,2017,38(3):1393-1401.
[16] Tsai CN, Yu SC, Lee CW, et al. SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo[J]. Oncogene,2020,39(24):4695-710.
[17] Zhang Y, Zhao W, Li S, et al. CXCL11 promotes selfrenewal and tumorigenicity of α2δ1 liver tumor-initiating cells through CXCR3/ERK1/2 signaling[J]. Cancer Lett,2019,449:163-171.
[18] Huang WY, Lin YS, Lin YC, et al. Cancer-Associated Fibroblasts Promote Tumor Aggressiveness in Head and Neck Cancer through Chemokine Ligand 11 and C-C Motif Chemokine Receptor 3 Signaling Circuit[J]. Cancers (Basel),2022,14(13):3141.
[19] He C, He L, Lu Q, et al.The functions and prognostic values of chemokine and chemokine receptors in gastric cancer, Am J Cancer Res,2022,12(7):3034-3050.
[20] Kaibori Y, Nagakubo D. CCR3 blockage elicits polyploidization associated with the signatures of epithelial-mesenchymal transition in carcinoma cell lines[J]. Cancer Gene Ther,2023,30(1):137-148.
[21] Zhang Z, Shao X, Wu H, et al. Prognostic Impact of Aberrantly Expressed Protein-coding Gene Associated With Gastric Cancer's Regulatory T Cells, Based on Online Databases[J]. Altern Ther Health Med,2023:AT7970.
[22] Hou Y, Qiao S, Li M, et al. The gene signature of tertiary lymphoid structures within ovarian cancer predicts the prognosis and immunotherapy benefit[J]. Front Genet,2023,13:1090640.
[23] Chai S, Wen Z, Zhang R, et al. CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma via the PI3K/AKT signaling pathway[J]. PeerJ,2022,10:1-27.
[24] Zhou X, Liao X, Wang X, etal. Clinical significance and prospective molecular mechanism of CC motif chemokine receptors in patients with earlystage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy[J]. Oncol Rep,2019,42(5):1856-1868.
[25] Zhong X, Wang X, Sun Q. CCL2/ACKR2 interaction participate in breast cancer metastasis especially in patients with altered lipid metabolism[J]. Med Hypotheses,2021,158:110734.
[26] Sjöberg E, Meyrath M, Milde L, et al. A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer[J]. Clin Cancer Res,2019,25(12):3702-3717.
[27] Pączek S, Łukaszewicz-Zając M, Mroczko B. Chemokines-what is their role in colorectal cancer? Cancer Control,2020,27(1):1073274820903384.
[28] Wei C, Yang CG, Wang SY, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis[J]. Mol Cancer,2019,18(1):64.
[29] Cheruku S, Rao V, Pandey R, et al. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy[J]. Int Immunopharmacol,2023,116:109569.